Skip to content
The Nexus
DossierENTITY

Lot 504950

Coverage of Lot 504950 in the Nexus archive.

Earliest in view: Aug 26 · 11:39 UTCMost recent: Aug 26 · 11:39 UTC
Co-mentioned in this coverage
Vitruvias Therapeuticsorganization1U.S. Food and Drug Administrationorganization1Alabamaplace1Thyroid tabletstopic1superpotenttopic1
Recent coverage
  • HEALTHAug 26 · 11:39 UTCWSOC ABC CHARLOTTE
    Recall alert: Vitruvias Therapeutics recalls thyroid tablets over ‘superpotent’ concerns

    Vitruvias Therapeutics Inc. issued a nationwide recall of its 30-milligram thyroid tablets because testing confirmed the product had potential to be “superpotent.” The recall specifically affects Lot 504950, which was distributed from Jan. 31, 2025, to Sept. 30, 2025. Consumption of these superpotent tablets can lead to an overactive thyroid, causing symptoms such as weight loss or rapid heart rate.

Lot 504950 · Dossier · The Nexus